Journal Article

DKFZ-2018-00213

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.

Baertsch, M.-A. ; Hundemer, M. ; Hillengass, J.DKFZ* ; Goldschmidt, H. ; Raab, M.-S. (Last author)DKFZ*

2018
Wiley Interscience New York, NY [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1002/hon.2473

Abstract: In multiple myeloma (MM), the synergy between immunomodulatory drugs (IMiDs) and monoclonal antibodies (MABs) has been demonstrated in several pivotal trials. However, disease refractory to either class of compounds remains a major therapeutic challenge. We here report on 3 heavily pretreated MM patients who were refractory to pomalidomide as well as to MABs against CD38 (daratumumab) or CD20 (rituximab), respectively, but who responded to retreatment with the same agents in combination. Responses were durable with PFS of 7, 10 (ongoing), and 30 months from initiation of combination treatment. The combination of IMiDs with MABs directed against MM cell surface antigens can overcome refractoriness to both agents.

---

Contributing Institute(s):

1. E010 Radiologie (E010)
2. Experimentelle Therapien hämatologischer Neoplasien (G170)

Research Program(s):

1. 317 - Translational cancer research (POF3-317) (POF3-317)

Appears in the scientific report 2018

---

Database coverage:
; BIOSIS Previews ; Current Contents - Life Sciences ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; Nationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---